Last reviewed · How we verify
Clopidogrel, Prasugrel, Ticagrelor
These are P2Y12 platelet adenosine diphosphate receptor antagonists that inhibit platelet aggregation and reduce thrombotic events.
These are P2Y12 platelet adenosine diphosphate receptor antagonists that inhibit platelet aggregation and reduce thrombotic events. Used for Acute coronary syndrome (NSTEMI, STEMI), Prevention of stent thrombosis following percutaneous coronary intervention, Secondary prevention of cardiovascular events in patients with prior myocardial infarction or stroke.
At a glance
| Generic name | Clopidogrel, Prasugrel, Ticagrelor |
|---|---|
| Also known as | Plavix, Brilinta, Effient |
| Sponsor | Centre hospitalier de l'Université de Montréal (CHUM) |
| Drug class | P2Y12 receptor antagonist / Antiplatelet agent |
| Target | P2Y12 receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Clopidogrel, prasugrel, and ticagrelor are antiplatelet agents that block the P2Y12 receptor on platelets, preventing ADP-induced platelet activation and aggregation. They are used to reduce the risk of stent thrombosis and recurrent cardiovascular events in patients undergoing percutaneous coronary intervention or with acute coronary syndromes. These drugs are often used in dual antiplatelet therapy (DAPT) alongside aspirin.
Approved indications
- Acute coronary syndrome (NSTEMI, STEMI)
- Prevention of stent thrombosis following percutaneous coronary intervention
- Secondary prevention of cardiovascular events in patients with prior myocardial infarction or stroke
Common side effects
- Bleeding (major and minor)
- Dyspnea
- Bradycardia
- Rash
- Gastrointestinal bleeding
Key clinical trials
- Tailoring Bleeding Reduction Approaches in Patients Undergoing PCI (PHASE4)
- The Switching Antiplatelet-9 (SWAP-9) Study (PHASE4)
- Bariatric Surgery for the Reduction of cArdioVascular Events Randomized Controlled Trial (NA)
- ARCANGELO (itAlian pRospective Study on CANGrELOr)
- STEMI Treated With a Polymer-free Sirolimus-coated Stent and P2Y12 Inhibitor-based SAPT Versus Conventional DAPT (NA)
- VerifyNow to Optimise Platelet Inhibition in Coronary Acute Syndrome (PHASE4)
- Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO IV-EPIC 38) (NA)
- PCI With Guideline-Directed Medical Therapy for HFpEF Patients With Ischemic Cardiomyopathy (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: